This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

25 Jul 2011

Merck and Simcere to Form Joint Venture

Merck has agreed with China's Simcere Pharmaceutical Group to form a joint venture focused on providing improved access to quality medicines in major therapeutic areas.

Merck & Co announced last week that the company has signed to form a joint venture with China’s Simcere Pharmaceutical Group with the aim initially of offering branded pharmaceutical products for cardiovascular and metabolic diseases in China.


In the area of cardiovascular disease, the partnership will offer a combined portfolio of drugs, which includes Merck’s Zocor (simvastatin), Cozaar (losartan) and Renitec (enalapril) and Simcere’s Xinta (levamlodipine) and Shufutan (rosuvastatin).


In the metabolic disease area, the partnership aims to maximise access in China to sitagliptin, a DPP-IV inhibitor for the treatment of type 2 diabetes.

Related News